Wire · opportunities
Amneal Announces FDA Approval and Launch of Lanreotide Injection
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
Amneal Pharmaceuticals announced FDA approval and immediate launch of lanreotide injection, a long-acting oncology treatment with Competitive Generic Therapy designation, expanding their complex injectables portfolio and supporting growth in affordable medicines.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 18 Sep 2026 and 19 Sep 2026.
◆ ◆ The Wire takeaway
You can now compete in the lucrative long-acting oncology injectables market where Amneal’s FDA approval opens the door for generic entrants. Immediate launch backed by in-house manufacturing means the barrier of supply constraints is lowered for complex generics like lanreotide.
◆ Coverage
3 sources · first reported 18 Sep 2026 · latest 19 Sep 2026
◆ Related on Wire
◆ Topics